Navigation Links
HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
Date:12/15/2008

Collaboration will leverage HUYA's growing Chinese bioscience network

SAN DIEGO, Dec. 15 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Schering-Plough Corporation's subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.

"HUYA is quickly gaining a reputation as a key point of contact for members of the Chinese bioscience community looking to establish relationships with Western development partners," said Mirielle Gingras, PhD, President and CEO of HUYA. "Our agreement with Schering-Plough demonstrates both the effectiveness of our network in China, and our ability to leverage that network to benefit major development partners in the West. We are delighted to be forging this new alliance, and look forward to a fruitful collaboration."

Schering-Plough will gain access to HUYA's growing Chinese bioscience network comprising premier universities, government research institutions and bioparks throughout the country. HUYA already has agreements in place with several of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. The company is currently evaluating and following the progress of more than 500 drug development candidates.

HUYA's model is based on longevity of relationships with its Chinese partners to provide a continuous source of compounds rather than a one-time single compound strategy. The ongoing exchange of expertise and data is intended to lower risk and facilitate rapid and efficient clinical development in both China and the West.

HUYA currently has two Chinese drugs undergoing preclinical development in the US - HBI-3000 and HBI-8000. Both drugs, for cardiac fibrillation and oncology, respectively, have successfully passed US FDA pre-IND consultations.

HUYA's Innovative Co-Development Model

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. Leveraging the HUYA Integrated Co-development Model for partnering with Chinese research institutions and pharmaceutical companies, HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach HUYA is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its' Chinese partners to discuss and design clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"From my involvement with the cardiac fibrillation program, I have been impressed with the relationship that HUYA has forged with its Chinese partners," said Eric Topol, MD, Chief Academic Officer, Scripps Health, San Diego, CA. "HUYA's co-development model is an excellent system for developing new drugs and ultimately introducing them into the Western market."

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with three strategic offices in China, a broad Chinese compound portfolio, and a significant number of exclusive agreements with premier Chinese biotech centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.

    Contact:

    USA:
    Jan Tuttleman, PhD
    Vice President, Marketing
    HUYA Bioscience International, LLC
    (858) 798-8800
    jtuttleman@huyabio.com

    China:
    Ben Ni, PhD
    Head of Therapeutics
    HUYA Bioscience International, LLC
    86 (21) 51323312
    bni@huyabio.com

    Media Contacts:

    Amy Berry
    (415) 793-2258
    amyeberry@comcast.net

    Juliet Travis
    (510) 452-3771
    juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
2. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
3. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial
8. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
9. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):